Nutritional status monitoring for adults with gastroenteropancreatic neuroendocrine tumors
Official title: Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital
Run by University Hospital, Strasbourg, France · NCT07302100 · Data updated 2026-11-12
This project will see if nutrition problems are common and linked to outcomes in adults aged 18–70 being followed for gastroenteropancreatic neuroendocrine tumors at Strasbourg University Hospital.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | sunitinib, chemotherapy |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | December 12, 2024 |
| Main results expected | February 2026 |
| Study ends | February 2026 |
| Registry record updated | December 24, 2025 |
| Trial ID | NCT07302100 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 to 70 diagnosed with a gastric, pancreatic, or intestinal neuroendocrine tumor between 1 January 2000 and 30 November 2024 who are followed at the CHU de Strasbourg endocrine/nutrition service.
✕Probably not a fit
Patients outside the 18–70 age range, those not followed at CHU de Strasbourg, or those whose tumors were reclassified as non‑neuroendocrine by pathology are unlikely to receive direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will collect historical and current nutritional data from adults aged 18–70 who have been followed for gastroenteropancreatic neuroendocrine tumors at CHU de Strasbourg between 1 January 2000 and 30 November 2024. Investigators will record measures such as weight, body mass index, laboratory nutritional markers, and any documented nutritional interventions, and will relate these to tumor features and clinical outcomes. No experimental treatments are given; the protocol is descriptive and aims to characterize the prevalence and pattern of malnutrition in this patient group. Results are intended to inform nutritional screening and management pathways for patients with typically slow‑growing gastroenteropancreatic NETs.
Why it matters
Potential benefit: If successful, the study could help clinicians identify patients at risk of malnutrition earlier and guide nutritional care that may improve quality of life and clinical outcomes.
How similar studies have gone: Prior cancer research has shown that malnutrition predicts poorer outcomes and that nutritional interventions can improve results, but targeted evidence specifically for gastroenteropancreatic neuroendocrine tumors remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 to 70 years * Patients being monitored for a digestive neuroendocrine tumor (gastric, pancreatic, intestinal), diagnosed between January 1, 2000, and November 30, 2024 Exclusion Criteria: \- Tumor reclassified as non-neuroendocrine by histopathology
Where it's running
-
Service d'Endocrinologie, Diabétologie, Nutrition - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Philippe BALTZINGER, MD
- Email: philippe.baltzinger@chru-strasbourg.fr
- Phone: 33 3 88 12 75 82
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GEP-NET treatment patterns and outcomes in the U.S.
This study will see how newly diagnosed GEP-NET patients are treated in real-world settings and what their outcomes look like.
-
RYZ401 for solid tumors that express somatostatin receptors
This trial will try RYZ401, a targeted radiotherapy, in adults with neuroendocrine or other solid tumors that show somatostatin receptors to find a safe dose and see if it shrinks tumors.
-
Characterizing Gastroenteropancreatic Neuroendocrine Tumors Treated With Targeted Radionuclide Therapy
This study is trying to see if advanced imaging can help doctors choose the right patients for a specific cancer treatment for gastroenteropancreatic neuroendocrine tumors to improve their chances of success.
-
Using 68Ga-DOTATOC PET to evaluate gastroenteropancreatic neuroendocrine tumors
This study is testing if a special type of PET scan can help doctors better diagnose gastroenteropancreatic neuroendocrine tumors in adults.
-
Continuing somatostatin analogues for patients with advanced neuroendocrine tumors
This study is testing whether continuing somatostatin therapy helps people with advanced neuroendocrine tumors do better after their initial treatment compared to stopping the therapy when they start a new treatment.
-
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
This study is testing a new type of treatment using targeted alpha-particle therapy to see if it can help people with advanced neuroendocrine tumors that have a specific protein called SSTR2.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.